Valeant divests generic Benzaclin and Efudex to Mylan

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc. (Nasdaq: MYL).

This action was required under the consent order issued by the Federal Trade Commission (FTC) as part of the acquisition of Dermik, a dermatology unit of Sanofi (EURONEXT: SAN and NYSE: SNY), which was completed in December 2011. 

Source:

Valeant Pharmaceuticals International, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Therapeutics that target ceramides may help treat cardiometabolic disease